IL161588A0 - Method and composition for dry eye treatment - Google Patents

Method and composition for dry eye treatment

Info

Publication number
IL161588A0
IL161588A0 IL16158801A IL16158801A IL161588A0 IL 161588 A0 IL161588 A0 IL 161588A0 IL 16158801 A IL16158801 A IL 16158801A IL 16158801 A IL16158801 A IL 16158801A IL 161588 A0 IL161588 A0 IL 161588A0
Authority
IL
Israel
Prior art keywords
film
eye
composition
mixture
dry eye
Prior art date
Application number
IL16158801A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Novagali Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Novagali Pharma Sa filed Critical Yissum Res Dev Co
Publication of IL161588A0 publication Critical patent/IL161588A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
IL16158801A 2001-11-01 2001-11-01 Method and composition for dry eye treatment IL161588A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2001/001015 WO2003053405A1 (en) 2001-11-01 2001-11-01 Method and composition for dry eye treatment

Publications (1)

Publication Number Publication Date
IL161588A0 true IL161588A0 (en) 2004-09-27

Family

ID=11043109

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16158801A IL161588A0 (en) 2001-11-01 2001-11-01 Method and composition for dry eye treatment

Country Status (11)

Country Link
EP (1) EP1441696B1 (ja)
JP (1) JP2005513097A (ja)
CN (1) CN100335036C (ja)
AT (1) ATE468107T1 (ja)
AU (1) AU2002214233A1 (ja)
CA (1) CA2464243C (ja)
DE (1) DE60142187D1 (ja)
ES (1) ES2343512T3 (ja)
HK (1) HK1067316A1 (ja)
IL (1) IL161588A0 (ja)
WO (1) WO2003053405A1 (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
ATE439123T1 (de) * 2004-07-02 2009-08-15 Novagali Pharma Sa Verwendung von emulsionen zur intra- und periocularen injection
WO2006003519A2 (en) * 2004-07-02 2006-01-12 Novagali Pharma Sa Use of emulsions for intra: and periocular injection
WO2006009112A1 (ja) * 2004-07-16 2006-01-26 Taisho Pharmaceutical Co., Ltd. 水性点眼剤
DE602004017477D1 (de) 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
AU2005304034B2 (en) 2004-11-09 2012-02-16 Santen Sas Ophthalmic emulsions containing an immunosuppressive agent
WO2007042262A2 (en) * 2005-10-10 2007-04-19 Novagali Pharma Sa Ophthalmic emulsions containing prostaglandins
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
US8288348B2 (en) 2005-07-13 2012-10-16 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
PL1834635T3 (pl) * 2006-03-13 2012-01-31 Advancell Advanced In Vitro Cell Tech S A Stabilne układy nanokapsułek do podawania cząsteczek aktywnych
EP2319517B1 (en) 2006-06-01 2013-09-11 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101130058B (zh) * 2006-08-23 2011-10-05 华北制药集团新药研究开发有限责任公司 一种环孢菌素a眼用乳剂及其制备方法
WO2008120249A1 (en) * 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2308468A1 (en) 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
CN109010270B (zh) * 2018-09-03 2021-07-30 辅必成（上海）医药科技有限公司 一种阳离子材料制备的眼用乳

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101241A (en) * 1992-03-16 1997-11-20 Yissum Res Dev Co Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe

Also Published As

Publication number Publication date
DE60142187D1 (de) 2010-07-01
AU2002214233A1 (en) 2003-07-09
EP1441696A1 (en) 2004-08-04
CN1558751A (zh) 2004-12-29
HK1067316A1 (en) 2005-04-08
CN100335036C (zh) 2007-09-05
EP1441696B1 (en) 2010-05-19
JP2005513097A (ja) 2005-05-12
WO2003053405A1 (en) 2003-07-03
ES2343512T3 (es) 2010-08-03
CA2464243C (en) 2010-01-19
ATE468107T1 (de) 2010-06-15
CA2464243A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
HK1067316A1 (en) Method and composition for dry eye treatment
AU655919B2 (en) Artificial tears
JP2005513097A5 (ja)
ATE132366T1 (de) Zusammensetzung zur behandlung von dry eye erkrankungen
ES2183629T3 (es) Composicion detergente.
KR970704421A (ko) 비누 조성물(Soap Composition)
TNSN07200A1 (fr) Dibenzylamines et derives
BR9915536A (pt) Composição e método para cuidados com o tecido
BR9610849A (pt) Composição de limpeza pessoal e processo para a inibiçao da perda de umidade pela pele e proteção da pele
HUP0001775A2 (hu) Testtisztító szer
BR0011883A (pt) Composição, produto para cabelos, produto para pele, e, processo de tratamento dos cabelos ou da pele
DE3874479T2 (de) Loesung zur behandlung von "dry-eye"-erkrankungen.
KR870002830A (ko) 고농도-오일-함유 무수 발포성 조성물
ATE200974T1 (de) Haarwaschmittel mit konditionierenden eigenschaften die bestimmte haarkonditionierende ester enthalten
WO2019030458A3 (fr) Emulsion moussante a haute teneur en huile et ses utilisations, notamment pour l'hygiene corporelle
TR199800437T1 (xx) Mikro em�lsiyonlar.
BR9711832A (pt) Composições lìquidas para a limpeza pessoal que contêm óleos e tensoativos sintéticos
BR0212867A (pt) Emulsão de água-em-óleo, composição, e, métodos para umectar pele de mamìfero, para desinfetar tecido de mamìfero e para suprir um agente farmacêutico a um mamìfero
MA21492A1 (fr) Compositions en emulsions contenant des agents emulsionnants amphipathiques .
MXPA05003851A (es) Composicion cosmetica de tipo emulsion de agua en aceite que contiene una sal activa desodorante y un emulsor derivado de poliolefina que lleva al menos una parte polar.
US5639450A (en) Cleansing and conditioning cosmetic composition
KR101308959B1 (ko) 저자극성 세안용 파우더 조성물
WO2007132273A3 (en) Rinse-off therapeutic agents for treating skin
US20040016410A1 (en) Method for neutralizing offensive chemical odors
FR2806624B1 (fr) Systeme huile silicone/co-solvant concentre en matiere(s) active(s) cosmetique(s) liposoluble(s), emulsion et formulation cosmetiques correspondantes

Legal Events

Date Code Title Description
FF Patent granted